IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 6596 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9672    
    Printed222    
    Emailed18    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2003  |  Volume : 69  |  Issue : 2  |  Page : 109--113

Management of pemphigus vulgaris during acute phase


Dept. of Dermatology & STD, Command Hospitals, Air Force, Bangalore, India

Correspondence Address:
P K Kar
Dept. of Dermatology & STD, Command Hospitals, Air Force, Bangalore
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17642849

Rights and PermissionsRights and Permissions

We present our experience with 21 patients of pemphigus vulgaris seen over a period of 10 years managed in service hospitals during acute phase of the disease. Age groups of patients ranged from 25-45 years. Eighteen (85.7%) were young adults, 30-40 years of age. Fifteen (71.4%) were men and 6(28.6%) were women. All the cases were hospitalized in ICU, till the acute phase of the disease subsided. Complete hematological profile, urinalysis, serum biochemistry and repeated bacterial cultures from the skin were carried out in all patients at the time of admission and thereafter weekly. The treatment comprised of potassium permanganate lotion bath (1:10000) and 1 framycetin gauze dressing of the denuded areas, maintenance of fluid and electrolyte balance. All suspected infections and septicemia were treated with appropriate antibiotics. The corticosteroids were usually administered as a single dose of prednisolone 1 mg/kg/day. Cyclophosphamide was given at an initial dose of 50mg/day and the dose was escalated to 100mg/day. Once the bulk of the lesions were healed, the dose of corticosteroids was gradually lowered by approximately 50% every two weeks and cyclophosphamide was continued till patients were symptomfree. Out of 21 patients receiving corticosteroids, cyclophosphamide and other supportive therapy, 20(95%) had undergone clinical resolution of the disease. During follow up study 15(71.4%) patients remained symptom-free and undergone clinical remission. Five patients (23.8%) had relapse, out of which 4(19%) remained symptom free, after subsequent treatment. There was one death (4.7%) in our study.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow